Laboratorios Farmaceuticos ROVI (MC:ROVI) — Stock Price
Laboratorios Farmaceuticos ROVI (MC:ROVI) is currently trading at €58.70 EUR, up 0.60% today. Over the past 52 weeks, shares have ranged between €53.65 and €85.55. This page tracks Laboratorios Farmaceuticos ROVI's live share price on the MC exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Laboratorios Farmaceuticos ROVI (ROVI) total market value.
Laboratorios Farmaceuticos ROVI (ROVI) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Laboratorios Farmaceuticos ROVI's daily closing share price and trading volume on the MC exchange over the past year, giving a clear view of recent price momentum and liquidity.
Laboratorios Farmaceuticos ROVI Income Statement — Revenue, Profit & Earnings by Year
Laboratorios Farmaceuticos ROVI's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | €763.75 Million | €829.51 Million | €817.70 Million | €648.68 Million | €419.96 Million |
| Cost of Revenue | €285.40 Million | €346.17 Million | €298.08 Million | €263.86 Million | €178.65 Million |
| Gross Profit | €478.35 Million | €483.34 Million | €519.61 Million | €384.82 Million | €241.31 Million |
| Research & Development | — | €25.36 Million | €23.87 Million | €27.45 Million | €23.80 Million |
| SG&A | €17.69 Million | €125.27 Million | €12.78 Million | €12.71 Million | €11.41 Million |
| Total Operating Expenses | €298.80 Million | €263.09 Million | €263.76 Million | €203.34 Million | €163.88 Million |
| Operating Income | €179.54 Million | €220.25 Million | €255.85 Million | €181.57 Million | €74.68 Million |
| EBITDA | €207.69 Million | €245.81 Million | €281.49 Million | €204.72 Million | €93.28 Million |
| EBIT | €179.68 Million | €221.48 Million | €258.62 Million | €183.35 Million | €73.68 Million |
| Interest Expense | €2.35 Million | €941.00K | €849.00K | €905.00K | €1.07 Million |
| Income Before Tax | €177.69 Million | €220.41 Million | €257.97 Million | €182.63 Million | €72.58 Million |
| Income Tax Expense | €40.81 Million | €50.11 Million | €58.30 Million | €29.55 Million | €11.52 Million |
| Net Income | €136.88 Million | €170.34 Million | €199.67 Million | €153.08 Million | €61.06 Million |
Laboratorios Farmaceuticos ROVI Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Laboratorios Farmaceuticos ROVI's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | €832.02 Million | €799.88 Million | €878.70 Million | €732.68 Million | €574.44 Million |
| Total Current Assets | €491.57 Million | €509.33 Million | €623.07 Million | €506.36 Million | €364.58 Million |
| Cash & Equivalents | — | — | €44.42 Million | — | — |
| Short-term Investments | €227.00K | €-65.00K | €-65.00K | €-65.00K | €-65.00K |
| Net Receivables | €129.50 Million | €143.31 Million | €184.16 Million | €160.06 Million | €84.20 Million |
| Inventory | €329.95 Million | €337.97 Million | €311.94 Million | €245.47 Million | €227.20 Million |
| Property, Plant & Equipment | — | — | €215.54 Million | €181.78 Million | €155.40 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €250.48 Million | €256.39 Million | €357.32 Million | €261.70 Million | €200.74 Million |
| Total Current Liabilities | €156.65 Million | €199.84 Million | €293.89 Million | €190.39 Million | €122.89 Million |
| Long-term Debt | €80.50 Million | €38.58 Million | €46.04 Million | €52.52 Million | €53.94 Million |
| Net Debt | €87.22 Million | €40.10 Million | €-52.81 Million | €-25.89 Million | €20.36 Million |
| Total Stockholder Equity | €572.03 Million | €539.39 Million | €520.01 Million | €470.98 Million | €373.70 Million |
| Retained Earnings | €486.21 Million | €555.53 Million | €456.03 Million | €445.43 Million | €302.21 Million |
Laboratorios Farmaceuticos ROVI Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Laboratorios Farmaceuticos ROVI generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | €138.28 Million | €113.25 Million | €237.60 Million | €149.44 Million | €46.88 Million |
| Capital Expenditures | €62.22 Million | €55.19 Million | €51.39 Million | €40.94 Million | €39.69 Million |
| Free Cash Flow | €76.06 Million | €58.06 Million | €186.21 Million | €108.50 Million | €7.18 Million |
| Investing Cash Flow | €-81.06 Million | €-52.03 Million | €-57.15 Million | €-40.84 Million | €-39.62 Million |
| Financing Cash Flow | €-55.36 Million | €-160.84 Million | €-154.54 Million | €-62.73 Million | €-21.52 Million |
| Dividends Paid | €56.45 Million | €69.05 Million | €51.01 Million | €21.13 Million | €9.70 Million |
| Stock-Based Compensation | — | — | €0.00 | €1.40 Million | €0.00 |
| Depreciation | €28.02 Million | €24.33 Million | €22.87 Million | €21.36 Million | €19.59 Million |
| Change in Cash | €1.86 Million | €-99.62 Million | €25.91 Million | €45.87 Million | €-14.26 Million |
Laboratorios Farmaceuticos ROVI Earnings History — EPS Actual vs. Analyst Estimates
Track Laboratorios Farmaceuticos ROVI's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 06, 2026 | — | — | — |
| Feb 25, 2026 | — | — | — |
| Nov 06, 2025 | 1.13 | — | — |
| Jul 24, 2025 | 0.42 | — | — |
| May 08, 2025 | 0.35 | — | — |
| Feb 25, 2025 | 0.46 | — | — |
| Nov 07, 2024 | 1.36 | — | — |
| Jul 31, 2024 | 0.55 | — | — |